Hua Medicine Ltd. is a biotechnology company specializing in the development and commercialization of innovative drug therapies, primarily targeting diabetes and related metabolic diseases. Headquarte... Hua Medicine Ltd. is a biotechnology company specializing in the development and commercialization of innovative drug therapies, primarily targeting diabetes and related metabolic diseases. Headquartered in Shanghai, the company leverages global resources and collaborations to address unmet medical needs worldwide. Its flagship product, dorzagliatin, is an oral treatment designed to regulate glucose homeostasis in patients with Type 2 diabetes by activating glucokinase, the glucose sensor in the body. This unique therapeutic approach aims to restore natural insulin secretion and improve overall glucose control, particularly benefiting individuals with impaired renal function. Hua Medicine's research-driven pipeline emphasizes cutting-edge pharmaceutical solutions, contributing to advancements in diabetes care and signaling China's growing influence in global pharmaceutical innovation. Beyond its core focus, the company continually explores new therapeutic fields and market opportunities to expand its impact within the healthcare sector.Show lessShow more

Disclosures ESG Data Financial Data

Income Statement Balance Sheet Group Entities

Data not available

Financial Fundamentals data not yet covered for Hua Medicine

We have not yet reviewed Hua Medicine's disclosures for Financial Fundamentals data.

If this data is relevant to your work, you can submit a data coverage request and our team will investigate the company's disclosures and capture the data if available.

Would you like us to review Hua Medicine's data?

Start your 30-day free trial to request a data review for Hua Medicine.

Start Free Trial

Legal Center Contact Us